title: Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
abstract: Repurposing agents approved for other indications to radiosensitize tumors may be advantageous. The study by Hill and colleagues utilizes nelfinavir, an HIV protease inhibitor (PI), in combination with radiotherapy in rectal cancer in a prospective study. This combination may improve tumor perfusion and regression compared with radiotherapy alone.
authors.affiliation: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Raymond E
authors.initials: RE
authors.lastname: Meyn
authors.affiliation: Department of Clinical Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Sunil
authors.initials: S
authors.lastname: Krishnan
authors.affiliation: Department of Clinical Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. hskinner@mdanderson.org.
authors.forename: Heath D
authors.initials: HD
authors.lastname: Skinner
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D019888:Nelfinavir / Q000627:therapeutic use*; D000069473:Radiation Dose Hypofractionation; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D011838:Radiation-Sensitizing Agents; D019888:Nelfinavir